S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

MacroGenics Stock Forecast, Price & News

+0.10 (+3.39%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
51,675 shs
Average Volume
1.93 million shs
Market Capitalization
$187.06 million
P/E Ratio
Dividend Yield
Price Target

MacroGenics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
867.2% Upside
$29.50 Price Target
Short Interest
12.98% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.57mentions of MacroGenics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$98,800 Bought Last Quarter
Proj. Earnings Growth
From ($3.15) to ($2.50) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.32 out of 5 stars

Medical Sector

189th out of 1,428 stocks

Pharmaceutical Preparations Industry

82nd out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MacroGenics logo

About MacroGenics (NASDAQ:MGNX) Stock

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MGNX Stock News Headlines

Why Revlon Stock Jumped 32% Today - Nasdaq
Why MacroGenics Stock Is Skyrocketing Today
6 Analysts Have This to Say About Macrogenics
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$77.45 million
Book Value
$3.91 per share


Free Float
Market Cap
$187.06 million

MacroGenics Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MacroGenics stock.
View analyst ratings for MacroGenics
or view top-rated stocks.

What is MacroGenics' stock price forecast for 2022?

7 Wall Street research analysts have issued 12-month price targets for MacroGenics' shares. Their MGNX stock forecasts range from $18.00 to $40.00. On average, they anticipate MacroGenics' stock price to reach $29.50 in the next year. This suggests a possible upside of 867.2% from the stock's current price.
View analysts' price targets for MacroGenics
or view top-rated stocks among Wall Street analysts.

How has MacroGenics' stock performed in 2022?

MacroGenics' stock was trading at $16.05 at the start of the year. Since then, MGNX stock has decreased by 81.0% and is now trading at $3.05.
View the best growth stocks for 2022 here

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for MacroGenics

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) issued its quarterly earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.24. The biopharmaceutical company had revenue of $11.10 million for the quarter, compared to analyst estimates of $17.20 million. MacroGenics had a negative trailing twelve-month return on equity of 84.52% and a negative net margin of 303.19%. During the same period in the previous year, the company posted ($0.90) earnings per share.
View MacroGenics' earnings history

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:
  • Dr. Scott Koenig M.D., Ph.D., Pres, CEO & Director (Age 70, Pay $954.14k)
  • Mr. James Karrels, Sr. VP, CFO & Corp. Sec. (Age 55, Pay $577.9k) (LinkedIn Profile)
  • Mr. Eric Blasius Risser, Chief Operating Officer (Age 49, Pay $571.98k)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 68, Pay $612.21k)
  • Dr. Thomas M. Spitznagel Ph.D., Sr. VP of Technical Operations (Age 55, Pay $550.97k)
  • Dr. Christopher Shayne James M.D., VP of Investor Relations & Corp. Communications
  • Mr. Jeffrey Stuart Peters, Sr. VP & Gen. Counsel (Age 50)
  • Dr. Stephen L. Eck, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 67)
  • Ms. Lynn Cilinski, VP, Controller & Treasurer (Age 64)

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics CEO Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among MacroGenics' employees.

What other stocks do shareholders of MacroGenics own?

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $3.05.

How much money does MacroGenics make?

MacroGenics (NASDAQ:MGNX) has a market capitalization of $187.06 million and generates $77.45 million in revenue each year. The biopharmaceutical company earns $-202,120,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

How many employees does MacroGenics have?

MacroGenics employs 427 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for MacroGenics is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321.

This page (NASDAQ:MGNX) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.